The issue of pricing is a familiar discussion for the pharma industry and Ruchin Kansal, of Virtusa, believes that there is the potential for a win-win situation.
As Novartis looks to sell a major chunk of its generics portfolio in the US, in-PharmaTechnologist has a look back at some of the stories this year that have signposted larger, on-going trends in the US generics market.
The US FDA announced a task force has been formed to prevent the shortage of drugs, by addressing the ‘underlying structural concerns’ that allow this to happen.
Generic drugs in China must demonstrate bioequivalence (BE) to branded medicines under new CFDA rules prohibiting the use of locally-made generics as reference products.
Pfizer says it will decide in 2018 whether to split its generics and branded businesses but M&A experts are already predicting how the giant will get rid of its established drugs programme.
Merck KGaA last week confirmed that it is considering selling off
its generics division, prompting mass speculation over potential
buyers within the industry.
In France, sales of generic drugs are continuing to grow, helped by
a favourable regulatory regime and a wave of patent expiries on top
branded drugs, reports Phil Taylor.
The consolidation of the generic drugs industry continues, with
Novartis' unit Sandoz merging with two companies that will bring it
back into the number one position in the sector.
The growing loss of patent protection on blockbuster drugs over the
next few years and the rising need to contain spiralling healthcare
costs are going to lend significant impetus to the growth of
Europe's generics and biogenerics...
Faced with a raft of consolidation in the market for generic
pharmaceuticals, Germany's Merck KGaA has entered the fray with an
agreement to acquire most of NM Pharma, the Scandinavian generics
business of top drugmaker Pfizer.
Predictions that the generics industry will experience further
consolidation - made at the annual meeting of the International
Generic Pharmaceutical Alliance this week - have been swiftly
followed by the news that Sandoz is buying...
Israel's Teva has moved a step closer to consolidating its position
as the world's biggest generics manufacturer with the $3.4 billion
(€2.7bn) acquisition of US-based SICOR, which makes active
pharmaceutical ingredients...